Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Klapper

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Leukemia|March 25, 2025
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) TrialsP J Bröckelmann, H Müller, M Fuchs, et al.
Leukemia|August 19, 2016
Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphomaF Linke, M Harenberg, M M Nietert, et al.
Leukemia|June 27, 2008
Pathway activation patterns in diffuse large B-cell lymphomasS Bentink, S Wessendorf, C Schwaenen, et al.
Leukemia|November 25, 2015
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trialsE Hoster, C H Geisler, J Doorduijn, et al.
Pediatric Blood & Cancer|November 15, 2018
Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trialL Kurch, D Hasenclever, R Kluge, et al.
Leukemia|August 22, 2017
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencingA Zamò, J Pischimarov, M Schlesner, et al.
Leukemia|December 2, 2015
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locusE Leich, E Hoster, M Wartenberg, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Annals of Hematology|August 1, 2020
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysisM Pouyiourou, A Meyer, A Stroux, et al.
Leukemia|November 7, 2025
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving conceptK S Kurz, A Zamo, C Drewes, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Leukemia|March 25, 2025
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) TrialsP J Bröckelmann, H Müller, M Fuchs, et al.
Leukemia|August 19, 2016
Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphomaF Linke, M Harenberg, M M Nietert, et al.
Leukemia|June 27, 2008
Pathway activation patterns in diffuse large B-cell lymphomasS Bentink, S Wessendorf, C Schwaenen, et al.
Leukemia|November 25, 2015
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trialsE Hoster, C H Geisler, J Doorduijn, et al.
Pediatric Blood & Cancer|November 15, 2018
Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trialL Kurch, D Hasenclever, R Kluge, et al.
Leukemia|August 22, 2017
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencingA Zamò, J Pischimarov, M Schlesner, et al.
Leukemia|December 2, 2015
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locusE Leich, E Hoster, M Wartenberg, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Annals of Hematology|August 1, 2020
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysisM Pouyiourou, A Meyer, A Stroux, et al.
Leukemia|November 7, 2025
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving conceptK S Kurz, A Zamo, C Drewes, et al.
Pageof 9